# An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Study · id `cardio:ct-nct03060577` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03060577](<https://clinicaltrials.gov/study/NCT03060577>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03060577

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.

## Technical summary

Registry record NCT03060577. Non-randomized; no masking; primary purpose treatment. Start 2017-04-27 (actual); primary completion 2021-12-17 (actual). Results posted on 2023-03-24.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 382 participants (enrolled count; ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Started: 2017-04-27 (actual) (ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Primary completion: 2021-12-17 (actual) (ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Completion: 2021-12-17 (actual) (ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Results first posted: 2023-03-24 (ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Countries: United States; Canada; Germany; Netherlands; United Kingdom (ClinicalTrials.gov record NCT03060577, source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03060577-2023-03-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
- Acronym: ORION-3
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Symptomatic Atherosclerosis
- Condition: Type2 Diabetes
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): Inclisiran
- Intervention (Drug): Evolocumab
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial (`cardio:pubmed-36620965`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 717da5bf7cb9e076f6ce38a886c70bb4e571163143f3d7fb5d98329195c5900c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
